Subcutaneous birch pollen allergen immunotherapy with a depigmented polymerized extract shows only sustained and long‐term efficacy in a subgroup of monosensitized adults and adolescents with allergic rhinitis

Subcutaneous birch pollen allergen immunotherapy with a depigmented polymerized extract shows only sustained and long‐term efficacy in a subgroup of monosensitized adults and adolescents with allergic rhinitis

Abstract Background Allergen immunotherapy (AIT) is an approved treatment for seasonal respiratory allergic diseases. A depigmented polymerized birch pollen extract for subcutaneous allergen immunotherapy (SCIT) has been demonstrated to be efficacious and safe in patients allergic to birch pollen an...

Full description

Bibliographic Details
Main Authors: Natalija Novak, Margitta Worm, Petra Staubach, Marek Jutel, Angelika Sager, Oliver Pfaar
Format: Article
Language:English
Published: Wiley 2022-10-01
Series:Clinical and Translational Allergy
Subjects:
allergic rhinitis
birch pollen
long‐term
phase III
post‐treatment
subcutaneous allergen immunotherapy
Online Access:https://doi.org/10.1002/clt2.12185

Internet

https://doi.org/10.1002/clt2.12185

Similar Items